ARCT · Arcturus Therapeutics Holdings Inc.
$8.23
+0.37 (+4.71%)
At close · Aug 14
Market Cap
$233.92M
Shares
28.42M
Arcturus Therapeutics Holdings Inc. Earnings Call Transcripts
Every quarterly earnings call for Arcturus Therapeutics Holdings Inc. (ARCT) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▲448.6%
$13.37M
−$35.27M
'22 Q3
22-11-09
▲2666.5%
$160.29M
$117.35M
'22 Q4
23-03-28
▲1431%
$80.28M
$50.75M
'23 Q1
23-05-09
▼61.2%
$10.52M
−$52.55M
'23 Q2
23-08-07
▲237.6%
$45.14M
−$16.22M
'23 Q3
23-11-14
▼80.8%
$30.86M
−$11.71M
'23 Q4
24-03-07
▼52.7%
$38.01M
−$26.82M
'24 Q1
24-05-08
▲374%
$49.86M
−$17.22M
'24 Q2
24-08-05
▼7.7%
$41.67M
−$6.90M
'24 Q3
24-11-07
▼26.2%
$22.77M
−$30.00M
'24 Q4
25-03-06
▼22.7%
$29.38M
−$14.08M
'25 Q1
25-05-12
▼43.2%
$28.30M
−$9.18M
'25 Q2
25-08-11
▼58.8%
$17.15M
−$13.45M
'25 Q3
25-11-10
▼68.4%
$7.20M
−$29.08M
'25 Q4
26-03-03
▼93%
$2.06M
−$26.96M
'26 Q1
26-05-07
LATEST
▼89.5%
$2.96M
−$23.79M
'26 Q2
26-08-06
Earnings call
FY26 · Q2
2026-08-06
Arcturus Therapeutics Holdings Inc. Q2 FY2026 Earnings Call
Revenue
$2.96M
▼ 89.5% YoY Diluted EPS
$-0.84
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q1
2026-05-07
Arcturus Therapeutics Holdings Inc. Q1 FY2026 Earnings Call
Positive tone
OTC Deficiency / ARCT-810 Program
Cystic Fibrosis / ARCT-032 Program
Regulatory Progress with FDA
Revenue
$2.06M
▼ 93% YoY Diluted EPS
$-0.95
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-03-03
Arcturus Therapeutics Holdings Inc. Q4 FY2025 Earnings Call
Positive tone
ARCT-032 cystic fibrosis Phase II
ARCT-810 OTC deficiency development
STARR sa-mRNA platform validation
Revenue
$7.20M*
▼ 68.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-10
Arcturus Therapeutics Holdings Inc. Q3 FY2025 Earnings Call
Positive tone
Clinical Trial Enrollment Expansion
ARCT032 Cystic Fibrosis Program
Costave COVID-19 Vaccine
Revenue
$17.15M
▼ 58.8% YoY Diluted EPS
$-0.49
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-11
Arcturus Therapeutics Holdings Inc. Q2 FY2025 Earnings Call
Positive tone
ARCT-032 Cystic Fibrosis program
FDA regulatory alignment and Phase III planning
ARCT-810 OTC deficiency program
Revenue
$28.30M
▼ 43.2% YoY Diluted EPS
$-0.34
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-12
Arcturus Therapeutics Holdings Inc. Q1 FY2025 Earnings Call
Positive tone
ARCT-810 OTC deficiency program
KOSTAIVE COVID-19 vaccine commercialization
ARCT-032 Cystic Fibrosis Phase 2
Revenue
$29.38M
▼ 22.7% YoY Diluted EPS
$-0.52
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-03-06
Arcturus Therapeutics Holdings Inc. Q4 FY2024 Earnings Call
Positive tone
ARCT-032 Cystic Fibrosis Program
Meiji KOSTAIVE Sales Shortfall
KOSTAIVE Vaccine Approvals and Commercialization
Revenue
$22.77M*
▼ 26.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-07
Arcturus Therapeutics Holdings Inc. Q3 FY2024 Earnings Call
Confident tone
KOSTAIVE commercial launch in Japan
Arcalis manufacturing strategic asset
ARCT-032 cystic fibrosis program
Revenue
$41.67M
▼ 7.7% YoY Diluted EPS
$-0.26
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-05
Arcturus Therapeutics Holdings Inc. Q2 FY2024 Earnings Call
Confident tone
ARCT-032 cystic fibrosis therapeutic
ARCT-810 OTC deficiency program
Kostaive COVID-19 vaccine launch and regulatory progress
Revenue
$49.86M
▲ 374% YoY Diluted EPS
$-0.64
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-08
Arcturus Therapeutics Holdings Inc. Q1 FY2024 Earnings Call
Confident tone
Quadrivalent seasonal influenza vaccine program
Kostaive COVID-19 vaccine commercialization in Japan
ARCT-810 OTC deficiency program
Revenue
$38.01M
▼ 52.7% YoY Diluted EPS
$-1.00
▼ 153.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-03-07
Arcturus Therapeutics Holdings Inc. Q4 FY2023 Earnings Call
Confident tone
Kostaive COVID-19 Vaccine Approval and Launch
Manufacturing and Partnerships (CSL, Meiji, ARCALIS)
LUNAR-FLU (ARCT-2138) Seasonal Influenza Program
Revenue
$30.86M*
▼ 80.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-14
Arcturus Therapeutics Holdings Inc. Q3 FY2023 Earnings Call
Revenue
$45.14M
▲ 237.6% YoY Diluted EPS
$-0.61
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-07
Arcturus Therapeutics Holdings Inc. Q2 FY2023 Earnings Call
Revenue
$10.52M
▼ 61.2% YoY Diluted EPS
$-1.98
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-09
Arcturus Therapeutics Holdings Inc. Q1 FY2023 Earnings Call
Revenue
$80.28M
▲ 1431% YoY Diluted EPS
$1.87
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-03-28
Arcturus Therapeutics Holdings Inc. Q4 FY2022 Earnings Call
Revenue
$160.29M*
▲ 2666.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-09
Arcturus Therapeutics Holdings Inc. Q3 FY2022 Earnings Call
Revenue
$13.37M
▲ 448.6% YoY Diluted EPS
$-1.33
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-09
Arcturus Therapeutics Holdings Inc. Q2 FY2022 Earnings Call
Revenue
$27.09M
▲ 1254% YoY Diluted EPS
$-0.82
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-09
Arcturus Therapeutics Holdings Inc. Q1 FY2022 Earnings Call
Revenue
$5.24M
▲ 146.5% YoY Diluted EPS
$-1.94
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-02-28
Arcturus Therapeutics Holdings Inc. Q4 FY2021 Earnings Call
Revenue
$5.79M
▲ 158.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-08
Arcturus Therapeutics Holdings Inc. Q3 FY2021 Earnings Call
Revenue
$2.44M
▲ 4.5% YoY Diluted EPS
$-2.05
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-09
Arcturus Therapeutics Holdings Inc. Q2 FY2021 Earnings Call
Revenue
$2.00M
▼ 13.8% YoY Diluted EPS
$-2.07
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-10
Arcturus Therapeutics Holdings Inc. Q1 FY2021 Earnings Call
Revenue
$2.13M
▼ 19.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-03-01
Arcturus Therapeutics Holdings Inc. Q4 FY2020 Earnings Call
Revenue
$2.24M
▼ 24.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-09
Arcturus Therapeutics Holdings Inc. Q3 FY2020 Earnings Call
Revenue
$2.33M
▼ 29.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-10
Arcturus Therapeutics Holdings Inc. Q2 FY2020 Earnings Call
Revenue
$2.32M
▼ 77.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-07
Arcturus Therapeutics Holdings Inc. Q1 FY2020 Earnings Call
Revenue
$2.65M
▼ 39.2% YoY
Rev · 7q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-03-11
Arcturus Therapeutics Holdings Inc. Q4 FY2019 Earnings Call
Revenue
$2.97M
Rev · 6q
Audio
Transcript
Slides
8-K10-K
Showing 1–27 of 27 earnings calls
Key facts
CIK
1768224
CUSIP
03969T109
13F (30d)
129 filings
128 filers
Visit website
Investor relations